Economic aspects of the cardiology program expansion of additional drugs provision by effective lipidlowering drugs for hypercholesterolemia control

The federal program of preferential drug provision in cardiology shows its effectiveness. However, hypercholesterolemia (HCH) remains a significant problem in patients in whom high-dose statin therapy does not provide the target level of low-density lipoprotein cholesterol (LDL cholesterol). The solution to the problem lies in the plane of prescribing lipid-lowering drugs of a different mechanism of action, for example, inhibitors of the PCSK9 enzyme. To recommend the inclusion of such kind drugs in the program, it is necessary not only to have evidence of their life-saving effect, but also the economic feasibility of their use. Aim: to evaluate the economic efficacy of alirocumab (INN) including in the federal program for patients who have suffered an acute coronary event, are receiving statins and have an LDL CH level of 5.0 mmol/l and higher.

Materials and methods. Modeling was applied in a target group of 3029 patients of working age who had undergone ACS during the previous 12 months with severe, including familial, HCH, with LDL cholesterol 5.0 mmol/l and higher, receiving statins taking into account previously determined outcomes when using alirocumab + statins for 5 years. Direct medical and non-medical costs, as well as indirect costs, are identified. The cost-effectiveness analysis was applied from the point of view of the effectiveness of treatment (effects on mortality, temporary disability, disability) and direct health care costs (additional drug provision and outpatient follow-up, specialized, including high-tech, medical care in a 24‑hour hospital). Two healthcare technologies were compared: statin therapy and use of alirocumab + statins. The calculations used according to domestic methods used the cost of medical treatment, temporary disability, hospitalizations, loss of GDP and other parameters.

Results. Modeling has shown a decrease in mortality, morbidity and disability when using alirocumab in even the first year of use. The economic effect of alirocumab from a decrease in temporary disability in the 1st year is 304.5 mln rub., in the 2nd — 301.5 mln rub., in the 3rd — 321.1 mln rub., in the 4th — 333.1 mln rub. The estimated amount of prevented GDP losses from mortality in the target group for 4 years in the case of alirocumab use amounted to 1,260.2 mln rub. The annual amount of avoidable GDP losses from mortality in the target group in the case of alirocumab is 27–30 %. The annual average savings per patient in the case of alirocumab use are from 7 to 17 %. The greatest impact on reducing losses from disability and mortality of the target group is noted in the group of people aged 40–59 years. Only for this group, if alirocumab is used, it is possible to reduce losses from disability and mortality by 159.2 million rubles per year (83 % of the total economic effect). Starting from the 4th year of alirocumab use, it is possible to obtain a positive economic effect in terms of hospitalization costs.

Conclusion. When alirocumab is included in the program of additional drug provision in cardiology, the share of costs for the purchase of alirocumab for the target group may be only 0.01 %. At the same time, the economic effect of inclusion in the first year alone will amount to at least 393.4 million rubles of budget funds. The total amount of avoidable losses due to the alirocumab usage may amount to 1,638 million rubles over 4 years.

1. Приказ Министерства здравоохранения РФ от 29 сентября 2022 г. N 639н "Об утверждении перечня лекарственных препаратов для медицинского применения в целях обеспечения в амбулаторных условиях лиц, находящихся под диспансерным наблюдением, которые перенесли острое нарушение мозгового кровообращения, инфаркт миокарда, а также которым выполнены аортокоронарное шунтирование, ангиопластика коронарных артерий со стентированием и катетерная абляция по поводу сердечно-сосудистых заболеваний, в течение 2 лет с даты постановки диагноза и (или) выполнения хирургического вмешательства" (электронный ресурс). [Order of MoH RF 29.09.2022 #639n "On approval of the list of medicines for medical use in order to provide outpatient care to persons under dispensary supervision who have suffered stroke, myocardial infarction, as well as who underwent coronary artery bypass grafting, coronary artery angioplasty with stenting and catheter ablation for cardiovascular diseases, within 2 years from the date diagnosis and (or) surgical intervention". (In Russ.)]. Доступно по: https://base.garant.ru/405567511/. Ссылка активна на 02.11.2023).

2. Duan Y, Gong K, Xu S, et al. Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics. Signal Transduct Target Ther. 2022 Aug 2;7(1):265. doi: 10.1038/s41392-022-01125-5.

3. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41(1):111-188. doi: 10.1093/eurheartj/ehz455.

4. Клинические рекомендации “Нарушения липидного обмена”, 2023 г. (электронный ресурс) [Clinical Guidelines “Lipids’ metabolism disorders” (In Russ.)]. дата обращения Доступно по: https://cr.minzdrav.gov.ru/recomend/752_1. Ссылка активна на 02.11.2023.

5. Jaam M, Al-Naimi HN, et al. Comparative efficacy and safety among high-intensity statins. Systematic Review and Meta-Analysis. J Comp Eff Res. 2023 Mar;12(3):e220163. doi: 10.57264/cer-2022-0163.

6. Agnello F, Mauro MS, Rochira C, et al. PCSK9 inhibitors: current status and emerging frontiers in lipid control. Expert Rev Cardiovasc Ther. 2023 Nov 23:1-18. doi: 10.1080/14779072.2023.2288169.

7. Khan SA, Naz A, Qamar Masood M, Shah R. Meta-Analysis of Inclisiran for the Treatment of Hypercholesterolemia. Am J Cardiol. 2020 Nov 1;134:69-73. doi: 10.1016/j.amjcard.2020.08.018.

8. Schwartz GG, Szarek M, Bhatt DL, et al. Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial. Eur Heart J. 2023 Mar 5;44(16):1408-17. doi: 10.1093/eurheartj/ehad144.

9. Игнатьева В.И., Концевая А.В., Драпкина О.М., Деркач Е.В. Лекарственные препараты, влияющие на активность PCSK9: моделирование эффективности у пациентов, перенёсших инфаркт миокарда с неконтролируемой дислипидемией. Качественная клиническая практика. 2023;(2):59-69. [Ignatyeva VI, Kontsevaya AV, Drapkina OM, Derkach EV. Drugs influencing on PCSK9 activity: modelling of efficacy in patients who had myocardial infarction with uncontrolled dyslipidemia. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2023;(2):59-69. (In Russ.) doi: 10.37489/2588-0519-2023-2-59-69].

10. Государственный реестр предельных отпускных цен (электронный ресурс) обращение к ресурсу 02.11.2023. [Govt Reestr predelnikh otpusknih cen (In Russ.)]. accessed 02.11.2023 rosminzdrav.ru.

11. Инструкция по медицинскому применению препарата Пралуэнт. Электронный ресурс Государственный реестр лекарственных средств (rosminzdrav.ru), обращение к ресурсу 02.11.2023 [SmPC Praluent. Govt Reestr of medicines. (In Russ.)]. accessed 02.11.2023 rosminzdrav.ru.

12. ГОСТ Р 57525-2017 Национальный стандарт Российской Федерации. «Клинико-экономические исследования. Общие требования» (электронный ресурс). [GOST R 57525-2017 The national standard “Clinical-economic trials. Common requirements”. (In Russ.)]. Доступно по: https://docs.cntd.ru/document/1200146142. Ссылка активна на 02.11.2023.

13. Приказ Минэкономразвития России № 192, Минздравсоцразвития России № 323н, Минфина России № 45н, Росстата № 113 от 10.04.2012 «Об утверждении Методологии расчета экономических потерь от смертности, заболеваемости и инвалидизации населения» (электронный ресурс). [Order of the Ministry of Economic Development of the Russian Federation No. 192, Ministry of Health and Social Development of the Russian Federation No. 323n, Ministry of Finance of the Russian Federation No. 45n, Rosstat No. 113 dated 04/10/2012 "On approval of the Methodology for calculating economic losses from mortality, morbidity and disability of the population". (In Russ.)]. Доступно по: https://docs.cntd.ru/document/902344829. Ссылка активна на 02.11.2023.

14. Программа государственных гарантий бесплатного оказания гражданам медицинской помощи на 2023 год и на плановый период 2024 и 2025 годов» Постановление Правительства РФ от 29.12.2022 № 2497 (электронный ресурс). [Program of govt guaranties of free medical aid on 2023 and planned period for 2024-2025 yy. Govt Order #2497 at 29.12.2022 (In Russ.)]. Доступно по: pravo.gov.ru/document/view/0001202212310044. Ссылка активна на 02.11.2023.

15. Расшифровка клинико-статистических групп заболеваний для оплаты медицинской помощи, оказанной в стационарных условиях (Группировщик КСГ) на 2023 год. <Письмо> Минздрава России от 26.01.2023 N 31-2/И/2-1075 (ред. от 11.05.2023) "О методических рекомендациях по способам оплаты медицинской помощи за счет средств обязательного медицинского страхования" (вместе с "Методическими рекомендациями по способам оплаты медицинской помощи за счет средств обязательного медицинского страхования", утв. Минздравом России N 31-2/И/2-1075, ФФОМС N 00-10-26-2-06/749 26.01.2023) (электронный ресурс). legalacts.ru/doc/, обращение к ресурсу 02.11.2023. [On methodological guidelines on ways to pay for medical care at the expense of obligatory medical insurance" (together with "Methodological guidelines on ways to pay for medical care at the expense of obligatory medical insurance") Ministry of Health RF (In Russ.)]. Доступно по: legalacts.ru/doc/. Ссылка активна на 02.11.2023.

16. Приказ Минэкономразвития России, Минздравсоцразвития России, Минфина России, Росстата № 192/323н/45н/113 от 10 апреля 2012 года «Об утверждении Методологии расчета экономических потерь от смертности, заболеваемости и инвалидизации населения» (электронный ресурс). [About methodology of economic losses due to mortality, morbidity and disability approvement. Order. (In Russ.)]. Доступно по: https://www.garant.ru/products/ipo/prime/doc/70070542/. Ссылка активна на 02.11.2023.

17. Бойцов С.А., Алекян Б.Г., Шахнович Р.М., Ганюков В.И. Что меняется в лечении острого коронарного синдрома в Российской Федерации? Рациональная Фармакотерапия в Кардиологии. 2022;18(6):703-709. [Boytsov SA, Alekyan BG, Shakhnovich RM, Ganyukov VI. What is changing in the treatment of acute coronary syndrome in the Russian Federation? Rational Pharmacotherapy in Cardiology. 2022;18(6):703-709. (In Russ.)]. doi: 10.20996/1819-6446-2022-12-14.

18. Фармакоэкономика и фармакоэпидемиология — практика приемлемых решений / Ред. В. Б. Герасимов, А. Л. Хохлов, О. И. Карпов. — М.: Медицина, 2005. — 352с. [Pharmacoeconimcs and pharmacoepidemilogy — practice of the right decisions / Ed. VB Gerasimov, AL Khokhlov, OI Karpov. Moscow: Meditsina, 2005. (In Russ)].